These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26542327)

  • 1. Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
    Pal SK; Sonpavde G
    BJU Int; 2015 Dec; 116(6):839-40. PubMed ID: 26542327
    [No Abstract]   [Full Text] [Related]  

  • 2. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
    Bahl A; Masson S; Malik Z; Birtle AJ; Sundar S; Jones RJ; James ND; Mason MD; Kumar S; Bottomley D; Lydon A; Chowdhury S; Wylie J; de Bono JS
    BJU Int; 2015 Dec; 116(6):880-7. PubMed ID: 25639506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.
    Jayaram A; Attard G
    Nat Rev Urol; 2015 Jun; 12(6):312-3. PubMed ID: 26032550
    [No Abstract]   [Full Text] [Related]  

  • 5. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer.
    Al-Mansouri L; Gurney H
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):288-295. PubMed ID: 31313526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.
    Wallis CJD; Klaassen Z; Jackson WC; Dess RT; Reichert ZR; Sun Y; Spratt DE
    JAMA Netw Open; 2021 May; 4(5):e2110950. PubMed ID: 34028551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients].
    Penel N
    Bull Cancer; 2016 Sep; 103(9):714-6. PubMed ID: 27597565
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
    Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
    Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Blas L; Shiota M; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Int J Urol; 2024 Jul; 31(7):829-831. PubMed ID: 38441353
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer].
    Ecstein-Fraisse E; Su Z
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Yamamoto Y; Nonomura N
    Int J Urol; 2024 Jul; 31(7):831-832. PubMed ID: 38572670
    [No Abstract]   [Full Text] [Related]  

  • 15. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
    Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
    BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.
    Parente P; Ng S; Parnis F; Guminski A; Gurney H
    Asia Pac J Clin Oncol; 2017 Dec; 13(6):391-399. PubMed ID: 28488360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
    Taneja SS
    J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209520
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer.
    Gyawali B; Koomulli-Parambil S; Iddawela M
    Crit Rev Oncol Hematol; 2016 Jun; 102():118-24. PubMed ID: 27157868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.